Results 11 to 20 of about 172,205 (306)
One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma
Journal of Bone Oncology, 2021 EWS/FLI is the defining mutation of Ewing sarcoma. This oncogene drives malignant transformation and progression and occurs in a genetic background characterized by few other recurrent cooperating mutations. In addition, the tumor is absolutely dependent
Guillermo Flores, Patrick J. Grohar
doaj +1 more source
Mutation Profile of Well-Differentiated Thyroid Cancer in Asians [PDF]
Endocrinology and Metabolism, 2015 Recent advances in molecular diagnostics have led to significant insights into the genetic basis of thyroid tumorigenesis. Among the mutations commonly seen in thyroid cancers, the vast majority are associated with the mitogen-activated protein kinase ...
Young Shin Song +2 more
doaj +1 more source
Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation. [PDF]
, 2020 Mutation and translocation of fibroblast growth factor receptors often lead to aberrant signaling and cancer. This work focuses on the t(8;22)(p11;q11) chromosomal translocation which creates the breakpoint cluster region (BCR) fibroblast growth factor ...
Bisom-Rapp, Ezra W +4 more
core +2 more sources
Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer. [PDF]
PLoS ONE, 2015 TMPRSS2-ERG junction oncogene is present in more than 50% of patients with prostate cancer and its expression is frequently associated with poor prognosis.
Giorgia Urbinati +6 more
doaj +1 more source
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins [PDF]
Proceedings of the National Academy of Sciences, 2013 Significance ROS1 fusion kinases are critical oncogenes in several malignancies, suggesting that ROS1 inhibitors are likely to be effective molecularly targeted therapies in these patients. Although phase I/II clinical trials using the ALK/ROS1 inhibitor crizotinib to treat ROS1 fusion-harboring non–small-cell lung cancer ...
Monika A, Davare +10 more
openaire +2 more sources
A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells. [PDF]
, 2016 The MST1R gene is overexpressed in pancreatic cancer producing elevated levels of the RON tyrosine kinase receptor protein. While mutations in MST1R are rare, alternative splice variants have been previously reported in epithelial cancers.
Babicky, M +10 more
core +5 more sources
Detecting and targetting oncogenic fusion proteins in the genomic era [PDF]
Biology of the Cell, 2015 The advent of widespread cancer genome sequencing has accelerated our understanding of the molecular aberrations underlying malignant disease at an unprecedented rate. Coupling the large number of bioinformatic methods developed to locate genomic breakpoints with increased sequence read length and a deeper understanding of coding region function has ...
Monika A, Davare, Cristina E, Tognon
openaire +2 more sources
Cell Reports, 2015 Transcription factor fusion proteins can transform cells by inducing global changes of the transcriptome, often creating a state of oncogene addiction.
Eleni M. Tomazou +8 more
doaj +1 more source
Scientific Reports, 2023 Gene fusions caused by cytogenetic aberrations play important roles in the initiation and progression of cancers. The recurrent MTAP-ANRIL fusion gene was reported to have a frequency of greater than 7% in melanoma in our previous study.
Zhuoying Lin +5 more
doaj +1 more source
E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domai [PDF]
, 2006 Human papillomavirus type 16 E5 protein (HPV-16 E5) is expressed early in papillomavirus infection and is localised primarily in the cell Golgi apparatus (GA) and endoplasmic reticulum. E5 prevents transport of the major histocompatibility class I (MHC I;
Adam +30 more
core +1 more source